https://www.polity.org.za
Deepening Democracy through Access to Information
Home / Covid-19 News RSS ← Back
Africa|Health|Products
Africa|Health|Products
africa|health|products
Close

Email this article

separate emails by commas, maximum limit of 4 addresses

Sponsored by

Close

Article Enquiry

ImmunityBio plans trial for second Covid-19 shot in South Africa

Close

Embed Video

ImmunityBio plans trial for second Covid-19 shot in South Africa

Covid-19 vaccine

28th September 2021

By: Bloomberg

SAVE THIS ARTICLE      EMAIL THIS ARTICLE

Font size: -+

ImmunityBio, the US company controlled by biotech billionaire Patrick Soon-Shiong, is planning to conduct a trial for a second Covid-19 shot in South Africa.

The new vaccine will combine the use of both ribonucleic acid, or RNA, and deoxyribonucleic acid, or DNA, as well as the adenovirus used in a an inoculation that’s already being tested, Soon-Shiong said in an interview.

Advertisement

ImmunityBio is already running local trials of an earlier dose, known as the hAd5 T-cell vaccine, and will test it as a booster for South African healthworkers who have received Johnson & Johnson’s vaccine.

The new programme’s co-ordinators “will likely start enrolling by mid-November, contingent on getting the necessary approvals” from the South African Health Products Regulatory Authority and the trial’s ethics committee, said Shabir Madhi, a vaccinologist at Johannesburg’s University of the Witwatersrand, who will be running the process.

Advertisement

While drugmakers around the world have produced billions of approved Covid-19 vaccines to roll out across the globe, many international pharma companies such as ImmunityBio have turned their attention to second-generation doses that could be used to fight future coronavirus variants and potentially deadly new waves.

South Africa has been the site of a number of trials already, carried out by Pfizer, AstraZeneca, Johnson & Johnson, Novavax and Sinovac Biotech. Madhi ran both the AstraZeneca and Novavax initiatives.

The new vaccine is expected to bolster the production of both antibodies and T Cells that kill virus-infected cells.

“We hope that this then solves the problem of high antibodies and durable immunity,” Soon-Shiong said, adding that the trial will initially encompass the first two phases of the three-stage path to approval for emergency or general use.

At a later stage, ImmunityBio may also run a trial of a so-called subunit protein Covid-19 vaccine, Soon-Shiong said. Subunit vaccines use fragments of viruses to stimulate an immune response.

 

EMAIL THIS ARTICLE      SAVE THIS ARTICLE

To subscribe email subscriptions@creamermedia.co.za or click here
To advertise email advertising@creamermedia.co.za or click here

Comment Guidelines

About

Polity.org.za is a product of Creamer Media.
www.creamermedia.co.za

Other Creamer Media Products include:
Engineering News
Mining Weekly
Research Channel Africa

Read more

Subscriptions

We offer a variety of subscriptions to our Magazine, Website, PDF Reports and our photo library.

Subscriptions are available via the Creamer Media Store.

View store

Advertise

Advertising on Polity.org.za is an effective way to build and consolidate a company's profile among clients and prospective clients. Email advertising@creamermedia.co.za

View options
Free daily email newsletter Register Now
Register Close